Consistent with other immunotherapies targeting the PD1/PD-L1 axis, greater response rates and longer survival have been observed in durvalumab-treated NSCLC patients with biopsy specimens that express ≥25% membranous PD-L1 TC compared to those with < 25% PD-L1 TC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.